Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 2
---
421,630,000 Ordinary Shares represented by 242,163 Depositary Shares, issuable upon the exercise of warrants issued in a May 2024 private placement, and (ii) 64,560,000 Ordinary Shares represented by 6,456 Depositary Shares, issuable upon the exercise of Placement Agent warrants issued in such private placement. The information included in this filing updates the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No. 1. Accordingly, this Post-Effective Amendment No. 1 concerns only the offer and sale of Ordinary Shares represented by Depositary Shares issuable from time to time upon exercise of such warrants that remain unexercised. All applicable registration fees were paid at the time of the original filing of the Registration Statement.

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.

<div align='center'>PRELIMINARY PROSPECTUS—SUBJECT TO COMPLETION, DATED MAY 8, 2025

2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares

___________________</div>

This prospectus relates to
the resale from time to time, by the selling shareholders identified in this prospectus, of up to an aggregate of 2,486,190,000 ordinary
shares, nominal value £0.00005 per share, or Ordinary Shares, of Biodexa Pharmaceuticals PLC, or the Company, represented by 248,619
American Depositary Shares, or Depositary Shares, consisting of (1) 2,421,630,000 Ordinary Shares represented by 242,163 Depositary Shares,
issuable upon the exercise of warrants issued in a May 2024 private placement, and (2) 64,560,000 Ordinary Shares represented by 6,456
Depositary Shares, issuable upon the exercise of warrant agent warrants issued in such private placement.

The selling shareholders
are identified in the table commencing on page 60. Each Depositary Share represents 10,000 Ordinary Shares. No Depositary Shares are being
registered hereunder for sale by us. We will not receive any proceeds from the sale of